GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market December 30, 2022
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 December 12, 2022
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting November 10, 2022
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting November 3, 2022
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update October 31, 2022
GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting October 6, 2022
GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies September 12, 2022
